Page last updated: 2024-12-06

dazoxiben hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dazoxiben hydrochloride is a potent and selective thromboxane synthase inhibitor. It was initially developed as an antiplatelet drug for the treatment of cardiovascular diseases, but its clinical use was discontinued due to hepatotoxicity concerns. Dazoxiben hydrochloride inhibits the enzyme thromboxane synthase, which is responsible for the synthesis of thromboxane A2 (TXA2), a potent vasoconstrictor and platelet aggregator. By blocking TXA2 production, dazoxiben hydrochloride reduces platelet aggregation and thrombus formation, thereby potentially preventing heart attacks and strokes. Despite its discontinuation as a therapeutic agent, dazoxiben hydrochloride remains an important research tool in the field of thrombosis and cardiovascular disease. It is used in experimental studies to investigate the role of TXA2 in various pathological processes, including platelet activation, inflammation, and vascular dysfunction. Furthermore, dazoxiben hydrochloride has been studied as a potential therapeutic agent for other conditions, such as cancer and inflammatory bowel disease, but its clinical applications in these areas are still under investigation.'

Cross-References

ID SourceID
PubMed CID53000
CHEMBL ID537708
SCHEMBL ID564080
MeSH IDM0318177

Synonyms (37)

Synonym
uk-37248-01
dazoxiben hydrochloride
dazoxiben hydrochloride (usan)
74226-22-5
D03663
4-(2-(1h-imidazol-1-yl)ethoxy)benzoic acid hydrochloride ,
dazoxiben hydrochloride [usan]
p-(2-imidazol-1-ylethoxy)benzoic acid monohydrochloride
benzoic acid, 4-(2-(1h-imidazol-1-yl)ethoxy)-, monohydrochloride
uk 37248-01
chembl537708 ,
uk-37,248-01
uk-37248
smr000059339
MLS000028316 ,
dazoxiben hcl
g5ai939lwf ,
unii-g5ai939lwf
SCHEMBL564080
PVKDFUXBDJPRGU-UHFFFAOYSA-N
4-[2-(1-imidazolyl)ethoxy]benzoic acid hydrochloride
DTXSID40225215
AKOS024277727
cambridge id 5210366
OPERA_ID_1053
sr-01000003207
SR-01000003207-2
HY-106067A
CS-0024780
BS-17515
S0541
dazoxiben hcl; uk-37248
mfcd00475663
Q27278786
D81509
4-(2-imidazol-1-ylethoxy)benzoic acid;hydrochloride
74226-22-5 (hcl)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"4 microM) inhibitory activities, was found to be orally bioavailable with a long duration of action and offered effective protection against mortality in a collagen-epinephrine-induced pulmonary thromboembolism model in mice."( 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Bruno, JJ; Hirschfeld, DR; Maloney, PJ; Martinez, GR; Walker, KA; Yang, DS, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" 7e, 9e, 13a, 13d, 18, 20, 21, and 23, when dosed orally in conscious spontaneously hypertensive rats."( 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Bruno, JJ; Hirschfeld, DR; Maloney, PJ; Martinez, GR; Walker, KA; Yang, DS, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency0.00600.007215.758889.3584AID588342
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency79.43283.981127.764939.8107AID504842
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
Smad3Homo sapiens (human)Potency4.46680.00527.809829.0929AID588855
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency10.49720.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency3.54810.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.01400.00091.230410.0000AID213124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID221955Inhibition of ADP-induced platelet aggregation of human PRP in the presence of pig aortal microsomes (PAM)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID185808Effect of TXA2 synthase inhibitor (compound) on serum TXB2 level in rats at 50 mg/kg po, after 2 hr.1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID93290Inhibition of [14C]arachidonic acid induced platelet aggregation at 0.5 uM (Control TXB2 = 14.9+/-2.5)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID185806Ex vivo inhibition of blood platelet aggregation in rats at 100 mg/kg peroral dose after 8 hr1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID93286Inhibition of [14C]arachidonic acid induced platelet aggregation at 0.5 uM (Control 6-keto-PGF1-alpha = 1.45+/-0.6)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID185805Ex vivo inhibition of blood platelet aggregation in rats at 100 mg/kg peroral dose after 5 hr1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID93293Inhibition of [14C]arachidonic acid induced platelet aggregation at 5 uM (Control TXB2 = 14.9+/-2.5)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID120759Protection against mortality in pulmonary thromboembolism model in mice at 9 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID93294Inhibition of [14C]arachidonic acid induced platelet aggregation at 50 uM (Control TXB2 = 14.9+/-2.5)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID117585Time course of protection against mortality in a pulmonary thromboembolism model in mice after -3h1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID117584Time course of protection against mortality in a pulmonary thromboembolism model in mice after -1h1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID213124Inhibitory activity against human thromboxane synthetase1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives.
AID93288Inhibition of [14C]arachidonic acid induced platelet aggregation at 50 uM (Control 6-keto-PGF1-alpha = 1.45+/-0.6)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID93287Inhibition of [14C]arachidonic acid induced platelet aggregation at 5 uM (Control 6-keto-PGF1-alpha = 1.45+/-0.6)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID120752Protection against mortality in pulmonary thromboembolism model in mice at 1 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID117586Time course of protection against mortality in a pulmonary thromboembolism model in mice after -5h1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID120754Protection against mortality in pulmonary thromboembolism model in mice at 30 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID117587Time course of protection against mortality in a pulmonary thromboembolism model in mice after -7h1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID185804Ex vivo inhibition of blood platelet aggregation in rats at 100 mg/kg peroral dose after 3 hr1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID120750Protection against mortality in pulmonary thromboembolism model in mice at 12 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]